August 2013 | The Journal of Targeted Therapies in Cancer

September 16, 2013

Regorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer. Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.

September 11, 2013

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

September 04, 2013

The efficacy of combining two immunotherapy agents will be assessed in a randomized, double-blind phase III study.

September 04, 2013

The use of tyrosine kinase inhibitors (TKIs) to inhibit BCR-ABL protein in chronic myeloid leukemia (CML) is one of the major milestones in modern oncology.

August 29, 2013

Clinical study results presented at the 2013 American Society of Clinical Oncology Annual Meeting may offer new hope for patients with chronic lymphocytic leukemia.

August 26, 2013

The dependence of cancer cells on the continued activity of specific oncogenes for proliferation and survival can be explored for drug development.

August 23, 2013

Long-term safety and efficacy results from COU-AA-302 in mCRPC, and efficacy and safety data for enzalutamide monotherapy were among the ASCO 2013 Annual Meeting presentations that extended clinically useful information for the care of patients with prostate cancer.

August 21, 2013

A dual-target PI3 kinase inhibitor demonstrated activity in several types of relapsed and refractory non-Hodgkin lymphoma.

August 20, 2013

The standard of care for metastatic renal-cell carcinoma (RCC) prevailed in a randomized comparison of everolimus and sunitinib as first-line therapy.

August 19, 2013

Dual HER2-targeted neoadjuvant therapy for early breast cancer did not significantly improve the pCR rate compared with a single anti-HER2 agent plus chemotherapy.

August 16, 2013

The presence or absence of RAS mutations should dictate use of panitumumab in combination with FOLFOX chemotherapy for patients with metastatic colorectal cancer.

August 13, 2013

Adding everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer and provided clues to the origin of trastuzumab resistance.